Evidence map›Paper›PMID 26056509›Full record

ArticleClinical Medicine Insights. Oncology2015

Transcriptome Analysis of Minimal Residual Disease in Subtypes of Pediatric B Cell Acute Lymphoblastic Leukemia.

Jitsuda Sitthi-Amorn, Betty Herrington, Gail Megason, Jeanette Pullen, Catherine Gordon, Shirley Hogan, Tejaswi Koganti, Chindo Hicks

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical Medicine Insights. Oncology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jitsuda Sitthi-AmornDivision of Hematology Oncology, Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS, USA.
Betty HerringtonDivision of Hematology Oncology, Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS, USA.
Gail MegasonDivision of Hematology Oncology, Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS, USA.
Jeanette PullenDivision of Hematology Oncology, Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS, USA.
Catherine GordonDivision of Hematology Oncology, Department of Pediatrics, University of Mississippi Medical Center, Jackson, MS, USA.
Shirley HoganDepartment of Pharmacy Practice, University of Mississippi School of Pharmacy, Jackson, MS, USA.
Tejaswi KogantiCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA.
Chindo HicksCancer Institute, University of Mississippi Medical Center, Jackson, MS, USA. ; Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute lymphoblastic leukemia (ALL) is the most common childhood cancer and the leading cause of cancer-related death in children and adolescents. Minimal residual disease (MRD) is a strong, independent prognostic factor. The objective of this study was to identify molecular signatures distinguishing patients with positive MRD from those with negative MRD in different subtypes of ALL, and to identify molecular networks and biological pathways deregulated in response to positive MRD at day 46. We compared gene expression levels between patients with positive MRD and negative MRD in each subtype to identify differentially expressed genes. Hierarchical clustering was applied to determine their functional relationships. We identified subtype-specific gene signatures distinguishing patients with positive MRD from those with negative MRD. We identified the genes involved in cell cycle, apoptosis, transport, and DNA repair. We also identified molecular networks and biological pathways dysregulated in response to positive MRD, including Granzyme B, B-cell receptor, and PI3K signaling pathways.

Indexed as

B-cell acute lymphoblastic leukemiagene expressionminimal residual disease

Identifiers

PMID26056509
PMCPMC4444133

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.